Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response
- Resource Type
- article
- Source
- Frontiers in Immunology, Vol 11 (2020)
- Subject
glycogen synthase kinase-3 (GSK3) glycogen synthase kinase-3 (GSK-3) inhibitor COVID COVID-19 9-ING-41 GSK-3b inhibitor Immunologic diseases. Allergy RC581-607 - Language
- English
- ISSN
- 1664-3224